Michael Fenn

Michael Fenn

Michael is currently Head of External Innovation at Dewpoint Therapeutics, where he leads search & evaluation of new technologies & assets, and as a member of the corporate development team focusing on partnerships, competitive intelligence and strategy. Michael is also part of the investment team at Iaso Ventures, helping source deals, leading diligence for making investment decisions, and stress testing new company concepts for innovative biotech startups. He is particularly passionate about bridging the gap between academic research and company creation, having worked extensively at this interface of business and science. Michael brings with him broad experience in technology translation, basic & applied research, business strategy, and multi-disciplinary scientific expertise. Previously, Michael was Director of Healthcare & Life Sciences at Harvard Innovation Labs where he served as a pillar of Harvard’s entrepreneurial ecosystem, overseeing startup incubation and advising Harvardaffiliated founders. Michael also co-led planning of Life Lab Longwood, a new translational biotech incubator at Harvard Medical School and part of the $200M Blavatnik Therapeutics Initiative. He maintains a parttime appointment at Harvard as an ilab Innovation Fellow. Michael was formerly an Assistant Professor of Biomedical Engineering at Florida Institute of Technology where his lab focused on the bio-nano interface with applications in drug delivery, biosensing, and regenerative medicine. He successfully oversaw the spinout of two companies from his lab, including a YCbacked, ML-driven diagnostic startup that was later acquired. Michael received his Ph.D. in Biomedical Engineering, M.S. in Materials Science & Engineering, and B.S. in Chemistry/Biochemistry, all from the University of Florida.

RETURN TO HONOREE LIST